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2Abstract
Objectives
Androgen deprivation therapy effectively shrinks hormone naïve prostate cancer, both in the 
prostate and at sites of distant metastasis. However prolonged androgen deprivation generally 
results in relapse and androgen independent tumour growth which is inevitably fatal. The molecular 
events which enable prostate cancer cells to proliferate in reduced androgen conditions are poorly 
understood. Here we investigate the role of Hedgehog signalling in androgen independent prostate 
cancer.
Methods
The activity of the Hedgehog signalling pathway was analysed in cultured prostate cancer cells and 
circulating prostate tumour cells isolated from blood samples of patients with androgen independent 
prostate cancer. 
Results
Androgen independent prostate cancer cells were derived through prolonged culture in reduced 
androgen conditions, modelling hormone therapy in patients and expressed increased levels of 
Hedgehog signalling proteins. Exposure of cultured androgen independent prostate cancer cells to 
cyclopamine, which inhibits Hedgehog signalling, resulted in inhibition of cancer cell growth. The 
expression of the Hedgehog receptor PTCH and the highly prostate cancer specific gene 
DD3PCA3was significantly higher in circulating prostate cancer cells isolated from patients with 
androgen independent prostate cancer compared with samples prepared from normal individuals. 
There was an association between PTCH and DD3PCA3 expression and the length of androgen 
ablation therapy. 
Conclusions
Our data are consistent with reports implicating hedgehog signalling overactivity in prostate cancer
and suggest that Hedgehog signalling contributes to the androgen independent growth of prostate 
3cancer cells.  As systemic anti-hedgehog medicines are developed the Hedgehog pathway becomes 
a potential new therapeutic target in advanced prostate cancer. 
41. Introduction
Prostate cancer is the second leading cause of male cancer related deaths and the incidence of 
prostate cancer diagnosis is also increasing as life expectancy increases, awareness improves and 
PSA measurement is performed more frequently [1]. Androgen deprivation therapy can be used to 
shrink androgen dependent tumours, both in the prostate and at distant sites. Eventually androgen 
deprivation leads to androgen independent prostate cancer (AIPC) which progresses and undergoes 
metastasis despite low levels of serum testosterone [2]. Once the cancer becomes androgen 
independent the median survival is 20-24 months with the most effective chemotherapeutic regimes
[3,4]. AIPC may arise as a consequence of amplification or mutations affecting the activity of the 
androgen receptor or cell signalling pathways that enable prostate cancer cells to proliferate in 
reduced androgen conditions [5]. Developing diagnostic and therapeutic approaches that target 
AIPC therefore has significant potential for improving survival and quality of life for prostate 
cancer patients.
Hedgehog pathway activity is important in organogenesis and the plant steroidal alkaloid 
cyclopamine, a hedgehog pathway inhibitor is a profound teratogen [6]. In those organs in which 
Hedgehog signalling affects organogenesis it is frequently also involved in carcinogenesis, the 
prostate is one such organ [7]. The Hedgehog pathway has recently been implicated in prostate 
cancer development and metastasis [8]. Patched (PTCH) is the receptor for all three vertebrate 
Hedgehog proteins Sonic (SHH), Indian (IHH) and Desert (DHH). In the absence of Hedgehog, 
PTCH inhibits Smoothened (SMO), a G protein coupled-like receptor. When Hedgehog binds to 
PTCH, SMO is disinhibited and initiates a signalling cascade that results in activation of GLI 
transcription factors and increased expression of target genes (that include PTCH and GLI1) [9,10]. 
Hedgehog pathway overactivity has been shown to render prostate epithelial cells tumorigenic, 
while inhibition of the Hedgehog pathway induces apoptosis and decreases invasiveness of prostate 
cancer cells [8]. Recent studies have shown a high prevalence of Hedgehog activity in high grade or 
5metastatic prostate cancers [8,11,12], but the contribution of Hedgehog signalling to AIPC is 
unclear. 
To investigate the role of Hedgehog signalling in AIPC we used a cell line model to 
demonstrate that Hedgehog signalling is active and required for the growth of AIPC cells. To 
correlate our findings with clinical samples we used a published protocol to isolate prostate cancer 
circulating tumour cells (CTCs) from peripheral blood samples of patients with AIPC. CTCs are 
cells which have become detached from the primary prostate tumour and are migrating via the 
circulation to sites suitable for the development of metastatic lesions, and their detection has been 
associated with poor prognosis in breast and prostate cancer patients [13,14]. Our results suggest the 
Hedgehog signalling pathway represents a potential new therapeutic target in AIPC.
2. Methods
2.1. Cell and Tissue Culture
Androgen dependent LNCaP cells were obtained from the American Type Culture Collection (LGC 
Promochem, Teddington, UK). Androgen independent LNCaP C4-2, and C4-2B cells were 
purchased from Viromed Laboratories, Minnetonka, USA. LNCaP AR2 cells were generated 
through prolonged (9 months) culture of LNCaP cells in androgen free media. All cells were grown 
at 37 ºC in RPMI media without phenol red (Sigma-Aldrich, Gillingham, UK) supplemented with 
10% (v/v) fetal bovine serum (Invitrogen, Paisely, UK) or 10% (v/v) charcoal stripped FBS 
(Hyclone, Utah, USA), 2.4mM glutamine (Sigma-Aldrich, Gillingham, UK), 1% (v/v) pyruvate 
(Sigma-Aldrich, Gillingham, UK), penicillin and streptomycin (50U and 50µg/ml) (Invitrogen, 
Paisely, UK). Cells were treated with cyclopamine (Sigma-Aldrich, Gillingham, UK) as detailed.
2.2. MTT assay for cell proliferation
LNCaP cells were seeded onto 96 well plates at 2-4x104/well in 200µl media and synchronized in 
G0 (quiescent) phase of the growth cycle by culture in serum free medium. After 12 hours this 
serum free medium was replaced with RPMI containing serum and cyclopamine. After 48 hours 
620µl of the 5mg/ml MTT substrate (Sigma-Aldrich, Gillingham, UK) was added to each well, 
incubated for 1 hour, washed and absorbance measured spectrophotometrically at a wavelength of 
570 nm. All experiments were performed in triplicate.
2.3. Isolation of Circulating Tumour Cells (CTCs)
Peripheral blood samples were obtained from 15 patients (named according the format ABC 12) 
and 5 normal male subjects (named NORM 1-5, all under 40 years of age with no significant 
intercurrent illness). Two 10ml peripheral blood samples were collected in EDTA coated tubes 
(Greiner Bio-One, Stonehouse, UK), kept on ice and processed within three hours of collection. 
Samples were processed through Oncoquick (Greiner Bio-One, Stonehouse, UK) tubes, as per the 
manufacturer’s instructions. In order to further purify the CTCs the Oncoquick enriched samples 
were depleted of CD45 positive cells and positively selected for EpCAM expressing cells using 
AutoMACS™ (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The study was fully 
approved by the Local Research Ethics Committee (reference number 05/Q0602/48). 
2.4. RNA isolation, amplification and Quantitative PCR (QPCR) 
RNA was isolated from the samples using the RNeasy Mini kit (Qiagen, Crawley, UK). The 
MessageAmp™ II RNA amplification kit (Ambion, Foster City, USA) was used to amplify and 
prepare CTCs cDNA from CTCs RNA samples. LNCaP cDNA was synthesized following DNAse 
treatment by reverse transcription using Superscript III  (Invitrogen, Paisely, UK) with oligo-dT 
priming. QPCR was performed in triplicate on CTC and LNCaP cDNA using Platinum 
SYBR®Green qPCR Supermix-UDG  (Invitrogen, Paisely, UK) on an Opticon DNA Engine 2™. 
The primer sequences used to determine the relative expression of PTCH, GLI1, DD3PCA3 and
housekeeping gene β2-microglobulin were: PTCH-f CTCCCAAGCAAATGTACGAGCA; PTCH-r 
TGAGTGGAGTTCTGTGCGACAC; GLI1-f GAAGACCTCTCCAGCTTGGA; GLI1-r 
GGCTGACAGTATAGGCAGAG; DD3PCA3-f GGTGGGAAGGACCTGATGATAG; DD3 PCA3-r 
GGGCGAGGCTCATCGAT; β2-microglobulin-f TGAATTCGTATGTGTCTGGGT; β2-
microglobulin-r CCTCCATGATGCTGCTTACAT. In order to confirm that our cDNA samples 
7were not contaminated with genomic DNA we used GREX/INTRON primers which amplify a 
sequence across an intron/exon boundary. No PCR products were observed in the cDNA cell line 
samples indicating an absence of genomic DNA, whereas the appropriate sized product was 
amplified from genomic DNA (data not shown). To validate the specificity of the PTCH, GLI1, 
DD3PCA3 and β2-microglobulin primer sets standard curves for each primer set were generated using 
LNCaP C4-2B derived cDNA and single appropriately sized single products detected following 
agarose gel electrophoresis of the PCR products  (data not shown). All cDNA samples expressed
the housekeeping gene β2-microglobulin and this was used for normalization.
2.5. Antibodies and immunostaining
Primary antibodies used were as follows: PTCH (#sc-6149; Santa Cruz Biotechnology, Santa Cruz, 
USA), GAPDH (#9484; Abcam, Cambridge, UK) and EpCAM (#ab20160; Abcam, Cambridge, 
UK). Antibodies were used at concentrations recommended by the manufacturers. For westerns 
primary antibodies were incubated overnight at 4oC with blocking and visualised using an 
appropriate HRP-conjugated secondary antibody using enhanced chemiluminescence (GE 
Healthcare UK Ltd, Little Chalfont, UK). For immunofluoresence staining primary antibodies were 
incubated overnight in blocking buffer and detected using appropriate secondary antibodies. 
Nuclear counterstaining was performed using DAPI. Stained preparations were analysed on a Zeiss 
510 confocal microscope.
2.6. Statistics
Statistical analysis was performed using Student’s t-test and Pearson’s correlation coefficient. p
values <0.05 were considered significant (***).
3. Results
Androgens are essential for the optimal growth of the prostate cancer cell line LNCaP despite 
expression of a promiscuous gain-of function mutant AR [15]. We generated the LNCaP subline 
AR2 following 9 months of culture of parental LNCaP cells in androgen free media (AFM). We 
8also used androgen independent sublines LNCaP C4-2 and C4-2B which were originally isolated 
and characterised following growth in castrated athymic mice from the site of grafting (C4-2) or 
bony metastases (C4-2B) [16]. The derived cell lines showed a continuum of increasing growth 
rates in androgen free conditions (Table 1). To investigate the contribution of Hedgehog signalling 
to androgen independent cell growth we determined the mRNA expression levels of components of 
this pathway in LNCaP (androgen dependent LNCaP cells maintained in androgen containing 
medium), LNCaP-A (androgen dependent LNCaP cells maintained in androgen free medium for 
five days), LNCaP AR2, LNCaP C4-2 and LNCaP C4-2B cells (maintained in androgen free 
medium). QPCR was performed to determine the expression level of PTCH and GLI1 mRNA. 
There was significant up regulation of PTCH and GLI1 expression in LNCaP AR2, LNCaP C4-2 
and LNCaP C4-2B cells (Fig.1A) and the PTCH RNA changes correlated with increased expression 
of PTCH protein (Fig.1B), which is indicative of active Hedgehog signalling [10]. To verify the 
importance of the Hedgehog pathway to AIPC cell growth we used the SMO inhibitor cyclopamine 
which blocks Hedgehog signalling [17]. PTCH and GLI1 are both constituents of the hedgehog 
pathway and targets that are also up regulated as a consequence of Hedgehog signalling. 
Application of cyclopamine for 48 hours to androgen independent LNCaP C4-2B cells resulted in a 
significant decrease in expression of PTCH and GLI1 (Fig.1C), consistent with inhibition of
Hedgehog signalling activity. The growth of androgen independent LNCaP cells was also reduced 
by treatment with the Hedgehog pathway inhibitor. Using cyclopamine between 0.01-1000M there 
was minimal affect at the lowest dose and up to 90% growth inhibition at higher concentrations 
(Fig.1D). 
To investigate whether the Hedgehog pathway contributes to clinical cases of AIPC we 
isolated CTCs from 20ml peripheral blood samples of patients with advanced prostate cancer who 
(with the exception of SUY25) are on second line treatment having failed primary hormone therapy
(with a rising PSA in the face of castrate serum testosterone levels) and are therefore androgen 
independent, (clinical characteristics: age 53-89 years, median 76; last PSA 12-667ng/ml, median 
964; testosterone less than 0.7nmol/L and duration of hormone therapy 1.2-13.9 years, median 4.4, as 
detailed in Table 2). The use of CTCs is advantageous as biopsies are rarely performed on patients 
at this cancer stage and obtaining CTCs is a low risk minimally invasive technique compared to 
biopsy. CTCs were not detected in the normal controls whereas each prostate cancer patient sample 
contained more than 5 nucleated CD45 negative, EpCAM positive cells (Fig.2), which has been 
associated with poor prognosis in breast and prostate cancer patients [13,14]. We established the 
expression levels of the PTCH receptor RNA and the prostate cancer specific marker DD3PCA3
[18,19] in CTCs preparations from healthy controls and prostate cancer patients (Fig.3). PTCH and 
DD3PCA3 were expressed in all cancer patients CTCs and we observed very good discrimination 
between the normal subjects and the patient groups for PTCH and DD3PCA3. Although a low level 
of DD3PCA3 expression was found in one of the controls. Heterogeneity of expression was observed 
within the cancer patient samples and this has also been previously reported for other markers using 
PCR profiling of CTCs [20]. The expression of the androgen responsive prostate cancer marker 
DD3PCA3 in CTCs isolated from patients receiving androgen ablation therapy and having low levels 
of serum testosterone is consistent with the presence of AIPC cells in the CTCs samples. PTCH 
showed the most discriminatory power between prostate cancer patients and normal subjects due to 
the absence of detectable expression in normal subjects. No correlation was found between PTCH 
or DD3PCA3 expression levels and last PSA serum level (Fig.3), age (data not shown), or PSA 
velocity (calculated by gradient of best fit with at least 3 readings in the past 18 months; data not 
shown). PATCH and DD3PCA3 expression was very low in two patients (SUY25 and BAP20) who 
do not show radiologically detectable metastasis.
There was a strong correlation between the CTCs expression levels of PTCH and DD3PCA3, 
(Fig.4). Interestingly, we also observed that expression of PTCH protein tended to be highest in 
CTC isolated from patients who had received androgen ablation therapy for the longest periods of 
time (Fig.2) and a highly significant increase in the CTC expression levels of DD3PCA3 and PTCH 
RNA was found when the patients were dichotomised about the median duration of androgen 
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deprivation (Fig.5). In our cancer patient group there is 85% survival 12 months after CTCs
analysis, though there is no difference in survival between high or low expression of PTCH, further 
follow up will be required to determine long term survival affects.
4. Discussion
Hedgehog signalling is required for normal prostate development and several studies have recently 
reported that active Hedgehog signalling occurs in localized and metastatic prostate cancer
[8,11,12,21]. PCR analysis has shown that while hedgehog ligands are expressed abundantly in 
localized and metastatic prostate cancer, in metastatic lesions the expression of PTCH and GLI1 is 
dramatically increased and treatment of an aggressive prostate xenograft model with cyclopamine
prevented metastasis to the lung, whereas overexpression of Gli1 caused lung metastasis [8].  This 
is consistent with our observation that PATCH expression was very low in two patients (SUY25 
and BAP20) who do not show radiologically detectable metastasis. On this basis inhibiting 
Hedgehog activity has been described as having “tremendous promise for controlling advanced 
prostate cancer” [22]. However, whether Hedgehog activity is also of importance in the 
development and progression of AIPC is unclear. In this study, we show that Hedgehog signalling 
is active in AIPC. We observed increased expression of components of the Hedgehog signalling
pathway in androgen independent LNCaP sub-lines and in CTC isolated from patients with AIPC. 
In addition targeting Hedgehog activity also inhibited growth of AIPC cells, consistent with the 
antiproliferative results recently reported following treatment of a spontaneously arising separate 
androgen independent LNCaP C81 subline with cyclopamine [5]. 
We found significant expression in CTC isolated from patients with AIPC of PTCH, 
consistent with active Hedgehog signalling and this correlated with expression of the prostate 
cancer specific marker DD3PCA3. This is the first reported expression of PTCH and DD3PCA3 RNA
in prostate cancer CTCs. Interestingly, there was heterogeneity in the expression of PTCH in the 
isolated AIPC patient CTCs, similar to the relative expression reported for other markers using PCR 
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profiling of CTCs [20]. We also found a significant association between the duration of patient 
androgen deprivation therapy and the level of PTCH expressed. With patients who had received
androgen deprivation for longer periods of time expressing higher levels of PTCH. Increased 
Hedgehog signalling could further promote the growth or metastasis of AIPC cells in these patients. 
However, as there is 85% survival 12 months after CTCs analysis in our prostate cancer patient 
group, additional follow up will be necessary to determine if Hedgehog signalling affects long term 
survival.
Profiling of CTCs has the potential to identify prostate patients where the Hedgehog
signalling pathway is active. Thus enabling targeted treatments in prostate cancer, similar to breast 
cancer where Herceptin therapy is targeted to the 25% of advanced or metastatic breast cancers that 
are ErbB2 (HER2) positive. At present, there is no clinically available treatment that specifically
targets the Hedgehog signalling pathway. However the SMO inhibitor cyclopamine, which we show 
can be used to inhibit AIPC cell proliferation, along with other Hedgehog signalling targeting 
compounds are currently being developed (Curis, USA) and a Phase I clinical trial of a systemically 
administered small molecule Hedgehog antagonist for testing in advanced cancer has been initiated 
(Genentech, USA). A combination of EGFR receptor gefitinib and cyclopamine has also recently 
been shown to improve the cytotoxic effects of docetaxel on cultured metastatic prostate cancer 
cells [23] and we have found strong synergistic effects on AIPC cell growth from combination 
treatments of cyclopamine with the ErbB signalling inhibitors gefitinib or lapatinib (unpubl. data., 
Shaw and Prowse).  The synergy may occur through a direct effect of EGF signalling selectively 
enhancing Hedgehog activity [24]. The use of small molecule Hedgehog antagonists as adjuvant 
therapies may therefore improve the survival rate observed with current regimes which are 
ineffective against AIPC and prove to be a useful addition to the armamentarium.
5. Conclusion
12
The Hedgehog signalling pathway is active in AIPC and PTCH positive CTC can be identified in 
patients with metastatic AIPC. As systemic anti-hedgehog medicines are developed targeting the 
Hedgehog pathway has potential to become a new therapeutic strategy in the treatment of advanced 
prostate cancer. 
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Table 1. Androgen independent growth of LNCaP sub-lines.  
Cell type Androgen independent growth.
(growth after 5 days in AFM/ growth in 
regular medium)
LNCaP 0.3
LNCaP AR2 0.7
LNCaP C4-2 1.0
LNCaP C4-2B 1.2
Table 2. Clinical characteristics of AIPC prostate cancer patients. Samples were anonymised according to the format ABC 12. ND=not determined; 
RT=radiotherapy; RP=radical prostatectomy; MAB=maximum androgen blockade; DA=dexamethosone and aspirin; CLE=cisplatin, lomustine, 
etoposide; LHRH=leutenising hormone therapy and Orchid= castration by bilateral subcapsular orchidectomy.
ID Age
Radiological
Metastasis
Previous 
Treatment
Years of 
Androgen 
Deprivation
Type of 
Medication
PSA 
Velocity
Last 
PSA
Castrate 
Testosterone 
Level 
BAP 20 87.08 N - 7.7 MAB 0.22 56.3 Y
PEJ 21 89.72 Y - 2.8 MAB 0.23 159.3 Y
BLR 22 53.26 Y - 1.6 MAB ND 19.0 Y
BRL 22 82.10 Y RT 7.9 MAB 0.60 199.6 Y
RYR 22 73.19 Y - 4.4 MAB 0.02 23.2 Y
FLR 23 72.67 Y RP 7.9 MAB 0.00 51.8 Y
ROA 23 76.01 Y - 2.4 DAS 3.73 471.0 Y
LAD 24 76.97 Y - 2.5 DA 0.25 152.5 Y
SUY 25 55.27 N RT 1.8 LHRH 0.03 43.6 N
GIP 28 63.38 Y RT 12.1 CLE 26.60 666.9 Y
MUH 30 86.67 Y - 10.3 MAB ND 164.1 Y
TUK 31 71.36 Y - 3.2 MAB 3.86 153.4 Y
FOJ 33 76.72 Y - 1.2 MAB -0.11 11.8 Y
HOD 34 77.88 ND - 13.9 Orchid 0.00 64.0 Y
LAP 34 68.91 Y - 5.1 LHRH 0.16 63.9 Y
Figure Legends
Figure 1. (A). QPCR showing relative expression of PTCH and GLI by LNCaP cells 
cultured in RPMI (LNCaP); LNCaP cells cultured in AFM for 5 days (LNCaP-A) and LNCaP 
AR2, C4-2 and C4-2B cultured in AFM. (B). Immunoblot showing expression of PTCH in
LNCaP cells and sublines. C. 14M cyclopamine treatment inhibits expression of PTCH and
GLI1 RNA in AIPC LNCaP C4-2B cells: control cells (lanes 1 and 3); 48hrs cyclopamine 
treatment (lanes 2 and 4). D. Concentration effect curve showing cyclopamine treatment 
inhibits growth of AIPC LNCaP C4-2B cells. The means -/+SD are shown, *** indicates 
significant difference in expression (p<0.05).
Figure 2. Representative immunofluorescence of CTC from patient <4 years ADT (BLR22: 
ADT 1.6 years) or > 4 years ADT (HOD34: HT 13.9 years) with PTCH and EpCAM 
antibodies.
Figure 3. QPCR showing relative expression of DD3PCA3 and PTCH in control (Norm1-5) 
and prostate cancer patient (ABC12) CTC samples. The expression of DD3PCA3 and PTCH is 
significantly higher (p<0.05) in the prostate cancer patient group. Patient samples are shown 
sorted left to right in order of last serum PSA measurement (FOJ33 lowest PSA-HOD34 
highest PSA).  No association exists between PSA measurement and expression of DD3PCA3
(Pearson's r = 0.318, p>0.05) or PTCH (Pearson's r = 0.191, p>0.05).
Figure 4. QPCR showing relative expression of DD3PCA3 and PTCH in prostate cancer patient 
CTC samples sorted in order of relative DD3PCA3 expression (PEJ21 lowest-RYR22 highest).
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A significant association exists between the two expression levels (Pearson's r = 0.832, 
p<0.05).
Figure 5. Box and whisker plots showing smallest and largest observation, median, 25th and 
75th centile values for DD3PCA3 and PTCH RNA expression in control and prostate cancer 
patient CTC samples, dichotomised for patient samples by duration of androgen deprivation 
therapy (ADT). Patients <4 years ADT: FOJ33, BLR22, SUY25, ROA23, LAD24, PEJ21, 
TUK31; Patients >4 years ADT: RYR22, LAP34, BAP20, FLR23, BRL22, MUH30, GIP28, 
HOD34. *** indicates statistically significant difference between dichotomised groups
p<0.05. 
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Figure 5
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